Drugs / Envorimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06888531 | Mar → Dec 2025 overdue | esophageal cancer | Henan Cancer Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Envorimab | “The treatment regimens include: Toripalimab: intravenous infusion, 240mg, D1, Q3W, for 2 consecutive doses; or Envorimab: subcutaneous injection, 400mg, D1, Q3W, for 2...” NCT06888531 ↗ |
| Route | Subcutaneous | “Envorimab: subcutaneous injection” NCT06888531 ↗ |